Headquartered in Salt Lake City, UT Fiscal year ends December NASDAQ: RXRX recursion.com
Recursion Pharmaceuticals (Nasdaq: RXRX) is a clinical-stage biotechnology company that uses AI to discover and develop drugs. Its core platform is the Recursion OS, an AI-native, end-to-end system that combines automated biology and chemistry labs, proprietary multimodal data and purpose-built AI models. The company uses it to identify novel biology, design small molecules and generate clinical evidence.
Its wholly owned pipeline spans oncology, rare disease and other areas with significant unmet need:
- **REC-4881:** oral MEK1/2 inhibitor for familial adenomatous polyposis, with FDA Orphan Drug and Fast Track designations; a registrational trial is targeted for 2H27.
- **REC-1245:** RBM39 molecular glue degrader for endometrial and other solid tumors.
- **REC-4539:** LSD1 inhibitor for solid tumors and hematology.
- **REC-7735:** PI3Kα H1047R inhibitor for solid tumors.
- **REC-102:** ENPP1 inhibitor for hypophosphatasia.
- **REC-617 (CDK7) and REC-3565 (MALT1):** the company is seeking partners for these.
Revenue comes mainly from discovery collaborations with large pharma partners, including upfront payments, milestones and potential royalties. The Sanofi partnership is in immunology and has delivered $144 million in payments to date. The Roche/Genentech partnership covers neuroscience and oncology maps of biology, with up to 40 potential programs and $216 million achieved to date. The company also earns grant revenue. Updated
A $10 million Sanofi milestone drove revenue 258% higher year over year, beating expectations and showing the AI platform converts into partner cash. October's raise pushed pro forma cash near $748.7 million, funding operations into 2029 and a registrational FAP trial targeted for the second half of 2027.
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one…
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully…
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from cap-weighted peers and creates…
AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age. Undoubtedly, it’s no mystery as to why many wish to be underweight in the…
Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the great GPU kingpin Nvidia…
Joey Frenette Nvidia’s Strategic AI Vision Nvidia (NASDAQ:NVDA | NVDA Price Prediction) has solidified its position as the backbone of the artificial intelligence (AI) revolution, with its graphics processing units (GPUs) driving the most…
Because Nvidia (NASDAQ:NVDA | NVDA Price Prediction) has become the face of artificial intelligence, investors tend to view it as a proxy for the technology. If you want to buy into AI’s…
Don’t look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns. Notably, the flagship…
Investors either love Cathie Wood or hate her. The founder of the Ark Invest family of exchange-traded funds can either be phenomenally successful or a dismal failure. While Wood formed her investment…
Recursion Pharmaceuticals (Nasdaq: RXRX) is a clinical-stage biotechnology company that uses AI to discover and develop drugs. Its core platform is the Recursion OS, an AI-native, end-to-end system that combines automated biology and chemistry labs, proprietary multimodal data and purpose-built AI models.
The Wall Street consensus 12-month price target for RXRX is $7.32.
